Physician profile
Sandra J Horning
NPI 1578607669
$2,486,405.97
in general payments reported to CMS, 2019-2025
3 companies · $538K in 2025
The $538K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $34K · 2021: $434K · 2022: $400K · 2023: $542K · 2024: $538K · 2025: $538K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1.6M · Travel and Lodging: $16K · Food and Beverage: $4,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,597,837.09 |
| Travel and Lodging | $16,115.16 |
| Food and Beverage | $4,019.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,038,903.65 | 2020-2025 | |
| Modernatx, INC. | $447,367.75 | 2021-2025 | |
| Genentech USA, INC. | $134.57 | 2025 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Horning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.